News

News

Pharm-Olam International Bolsters Client Outreach with Strategic Hire in Proposals and Contracts

Wednesday, August 17, 2016

Pharm-Olam International Ltd., a multinational, full-service Clinical Research Organization (CRO), serving the biopharmaceutical and medical device industries, announces the appointment of David Murcar to the position of Director, Proposals and Contracts. 

Pharm-Olam International Strengthens Country Leadership with Strategic Hire in Mexico

Monday, June 27, 2016

HOUSTON, TEXAS - Pharm-Olam International Ltd., a multinational, full-service Clinical Research Organization (CRO), serving the biopharmaceutical and medical device industries, announces the appointment of Fabiola Encinas as the Country Operations Manager for Mexico.  Ms. Encinas has over 11 years of experience in the management of development programs throughout Latin America specializing in local team leadership, ensuring efficient and effective trial management.

Pharm-Olam International Adds Regional Director, Clinical Operations

Tuesday, May 24, 2016

HOUSTON, TEXAS. Pharm-Olam International Ltd., a multi-national, full-service Clinical Research Solutions Organization to the biopharmaceutical and medical device industries, is pleased to welcome Miguel Salcedo to its management team as Regional Director, Clinical Operations.

Pharm-Olam International Awarded Six CRO Leadership Awards

Tuesday, May 10, 2016

HOUSTON, TEXAS – Pharm-Olam International Ltd., a multinational, full-service Clinical Research Organization (CRO) serving the biopharmaceutical and medical device industries, announced today it has won six CRO Leadership Awards.

Pharm-Olam Continues Global Expansion; Adds Full-Service Coverage in Asia-Pacific Region

Tuesday, January 12, 2016

Pharm-Olam International Ltd., a multi-national, full-service Clinical Research Solutions Organization to the biopharmaceutical and medical device industries, is proud to announce its expansion of Phase I-IV clinical trial services into the Asia-Pacific region.

This expansion includes the opening of legal entities in Vietnam, Philippines, South Korea, Malaysia, Thailand and Taiwan.

Pharm-Olam Strengthens Leadership Team with New Chief Financial Officer

Sunday, December 20, 2015

Financial OfficerPharm-Olam International Ltd., a multi-national, full-service Clinical Research Solutions Organization to the biopharmaceutical and medical device industries, is proud to announce the promotion of Natalie Gassen to the position of Chief Financial Officer.

Pharm-Olam International Expands to Larger Facility in Poland

Tuesday, October 13, 2015

Pharm-Olam International Ltd., a multi-national, full-service Clinical Research Solutions Organization (CRO) to biopharmaceutical and device industries, is proud to announce the relocation of its Polish location to a larger office to accommodate for its growing staff.

Pharm-Olam International Opens a New Office in Paris, France; Continues Global Expansion

Thursday, June 11, 2015

HOUSTON, TEXAS – Pharm-Olam International Ltd., a multi-national, full-service Clinical Research Solutions Organization (CRO) to biopharmaceutical and device industries, is proud to announce the opening of a new, fully-staffed office in Paris, France.

Pharm-Olam Releases Case Study on Automated Sample Retention for BA/BE

Thursday, March 12, 2015

Bioavailability and Bioequivalence (BA/BE) studies require samples of investigational product retained. Typically, this is performed manually and overseen by clinical monitors during site initiation. This manual approach is feasible for limited sites, but larger site numbers make manual retention less feasible. This case study reviews Pharm-Olam's Automated Sample Retention Solution that was used in a recent study.

To read the complete case study click here.

Pharm-Olam completes a Phase III Pulmonary Arterial Hypertension study

Thursday, February 12, 2015

Pharm-Olam was selected to provide development services for a Phase III study, which was designed to address the efficacy and safety for a compound for pulmonary arterial hypertension patients.

Pharm-Olam was responsible for:
  • The recruitment of 192 patients
  • Management of 17 sites in Russia, Belarus, and Ukraine
  • All regulatory, project management, and monitoring services

To view the case study and the lessons learned in this study, click here